Free Trial

HUTCHMED (HCM) Competitors

HUTCHMED logo
$15.68 +0.27 (+1.75%)
As of 03:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

HCM vs. MRNA, BPMC, VRNA, BBIO, ROIV, RVMD, ELAN, LEGN, GRFS, and TLX

Should you be buying HUTCHMED stock or one of its competitors? The main competitors of HUTCHMED include Moderna (MRNA), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Legend Biotech (LEGN), Grifols (GRFS), and Telix Pharmaceuticals (TLX). These companies are all part of the "pharmaceutical products" industry.

HUTCHMED vs. Its Competitors

HUTCHMED (NASDAQ:HCM) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

HUTCHMED presently has a consensus price target of $19.00, indicating a potential upside of 21.17%. Moderna has a consensus price target of $46.61, indicating a potential upside of 53.96%. Given Moderna's stronger consensus rating and higher probable upside, analysts clearly believe Moderna is more favorable than HUTCHMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HUTCHMED
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Moderna
4 Sell rating(s)
15 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.04

HUTCHMED has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, Moderna has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500.

HUTCHMED has higher earnings, but lower revenue than Moderna.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HUTCHMED$630.20M4.34$37.73MN/AN/A
Moderna$3.24B3.62-$3.56B-$8.73-3.47

8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 3.6% of HUTCHMED shares are held by company insiders. Comparatively, 11.0% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Moderna had 15 more articles in the media than HUTCHMED. MarketBeat recorded 21 mentions for Moderna and 6 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.22 beat Moderna's score of 0.22 indicating that HUTCHMED is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
HUTCHMED
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Moderna
10 Very Positive mention(s)
4 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Neutral

HUTCHMED has a net margin of 0.00% compared to Moderna's net margin of -105.67%. HUTCHMED's return on equity of 0.00% beat Moderna's return on equity.

Company Net Margins Return on Equity Return on Assets
HUTCHMEDN/A N/A N/A
Moderna -105.67%-28.69%-21.94%

Summary

Moderna beats HUTCHMED on 9 of the 15 factors compared between the two stocks.

Get HUTCHMED News Delivered to You Automatically

Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HCM vs. The Competition

MetricHUTCHMEDMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.74B$2.90B$5.50B$8.93B
Dividend YieldN/A2.69%5.38%4.12%
P/E RatioN/A21.2826.2519.86
Price / Sales4.34280.14415.14113.78
Price / Cash52.4041.8936.4957.06
Price / Book3.547.468.055.38
Net Income$37.73M-$55.05M$3.16B$248.50M
7 Day Performance1.29%2.25%1.78%2.78%
1 Month Performance15.29%7.17%4.74%5.84%
1 Year Performance-8.94%5.13%35.81%20.06%

HUTCHMED Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HCM
HUTCHMED
1.7684 of 5 stars
$15.68
+1.8%
$19.00
+21.2%
-12.2%$2.74B$630.20M0.001,811
MRNA
Moderna
4.3556 of 5 stars
$25.67
-0.9%
$46.61
+81.6%
-75.3%$10.02B$3.24B-2.945,800Trending News
Options Volume
Gap Up
BPMC
Blueprint Medicines
1.5411 of 5 stars
$128.40
+0.2%
$128.06
-0.3%
+17.5%$8.28B$508.82M-51.98640High Trading Volume
VRNA
Verona Pharma PLC American Depositary Share
2.556 of 5 stars
$97.05
+2.9%
$101.10
+4.2%
+483.4%$8.03B$42.28M-48.5330Positive News
Analyst Forecast
BBIO
BridgeBio Pharma
4.7079 of 5 stars
$42.17
+1.1%
$56.67
+34.4%
+69.8%$7.92B$221.90M-11.95400Analyst Forecast
Insider Trade
ROIV
Roivant Sciences
1.9285 of 5 stars
$11.50
+0.4%
$17.50
+52.2%
+1.0%$7.78B$29.05M-46.00860
RVMD
Revolution Medicines
4.4912 of 5 stars
$40.04
+1.0%
$67.08
+67.5%
-4.9%$7.39B$11.58M-10.01250Analyst Revision
ELAN
Elanco Animal Health
2.3219 of 5 stars
$13.36
-0.7%
$15.17
+13.5%
+2.5%$6.68B$4.44B18.059,000
LEGN
Legend Biotech
2.4528 of 5 stars
$33.85
-0.4%
$76.20
+125.1%
-21.1%$6.25B$627.24M-57.372,609Positive News
GRFS
Grifols
4.1197 of 5 stars
$8.37
-4.6%
$10.30
+23.1%
+43.3%$6.03B$7.81B7.1523,822Analyst Downgrade
TLX
Telix Pharmaceuticals
N/A$16.39
-4.4%
$22.00
+34.2%
N/A$5.80B$516.72M0.00N/AGap Down
High Trading Volume

Related Companies and Tools


This page (NASDAQ:HCM) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners